-
New Phase 3 trial of Duchenne gene therapy SGT-003 to begin dosing
A Phase 3 trial testing SGT-003, a gene therapy candidate for Duchenne muscular dystrophy (DMD), will
-
CureDuchenne invests in Satellos as it raises $57.2M to advance their Duchenne program through clinical trials
CureDuchenne Invests in Satellos to Advance a Mutation-Independent Duchenne TherapyLink to press release CureDuchenne is








